Actively Recruiting
A Study of NX-1607 in Adults With Advanced Malignancies
Led by Nurix Therapeutics, Inc. · Updated on 2025-09-09
345
Participants Needed
17
Research Sites
334 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
CONDITIONS
Official Title
A Study of NX-1607 in Adults With Advanced Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Measurable disease according to disease-specific criteria
- Metastatic or unresectable disease with prior standard treatments ineffective, unavailable, or unsuitable
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- At least 3 weeks or 5 half-lives since last systemic cancer therapy, or 2 weeks since radiotherapy, or 6 weeks since certain therapies
- Adequate organ and bone marrow function without growth factors (exceptions for DLBCL)
- Use of adequate contraception for patients of child-bearing potential during the study
- Willingness and ability to follow study restrictions
- Signed informed consent form
- Histological or cytological diagnosis of specified advanced cancers
- Accessible tumor or lymph node for biopsy (Phase 1b only)
You will not qualify if you...
- Active untreated brain metastases
- Uncontrolled illnesses such as poorly controlled hypertension, diabetes, or active infections requiring systemic therapy
- Primary refractory epithelial ovarian cancer (no response to first platinum regimen or relapse under 6 months)
- Psychiatric illness limiting study compliance
- Recent treatment with certain immunotherapies, stem cell transplants, systemic cancer therapies, or radiotherapies within specified time frames
- History of CAR-T therapy within 30 days before study drug
- Unresolved toxicities from previous therapies above Grade 1 except specific exceptions
- Prior Grade 3 or higher immune-related adverse events
- History of uveitis or active autoimmune disease requiring systemic treatment in past 2 years
- Inability to swallow capsules or gastrointestinal conditions affecting drug absorption
- Known allergies or intolerance to NX-1607 components
- Pregnant, breastfeeding, or planning pregnancy during study or specified post-treatment periods
- Men planning to father a child during study or specified post-treatment periods
- Major surgery within 4 weeks before first dose or planned during study or within 4 weeks after last dose
- Recent live vaccinations or COVID-19 vaccine within specified timeframes
- Active second malignancy except certain treated cancers or cancers in remission for at least 2 years
- HIV infection except well-controlled cases
- Active hepatitis infections except treated or controlled cases
- Recent use of systemic corticosteroids or immunosuppressive drugs above specified doses
- Recent use of high-dose biotin supplements above daily adequate intake
- Recent participation in other investigational product or device trials
- Significant cardiac events or conditions within 6 months before first dose
- Any condition or abnormality that could interfere with study participation or results as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 17 locations
1
City of Hope
Duarte, California, United States, 91010
Completed
2
University of Southern California
Los Angeles, California, United States, 90007
Actively Recruiting
3
University of California, San Francisco
San Francisco, California, United States, 94158
Actively Recruiting
4
University of Colorado School of Medicine
Aurora, Colorado, United States, 80045
Actively Recruiting
5
University of Chicago
Chicago, Illinois, United States, 60637
Actively Recruiting
6
University of North Carolina
Chapel Hill, North Carolina, United States, 27599
Actively Recruiting
7
University of Oklahoma
Oklahoma City, Oklahoma, United States, 73104
Actively Recruiting
8
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
9
University of Virginia
Charlottesville, Virginia, United States, 22908
Actively Recruiting
10
Fred Hutchinson Cancer Center
Seattle, Washington, United States, 98109
Actively Recruiting
11
Royal Marsden Hospital NHS Foundation Trust
Sutton, Surrey, United Kingdom, SM2 5PT
Actively Recruiting
12
Addenbrookes Cambridge University Hospital
Cambridge, United Kingdom, CB2 0QQ
Actively Recruiting
13
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom, G12 0YN
Actively Recruiting
14
Sarah Cannon Research Institute
London, United Kingdom, W1G 6AD
Actively Recruiting
15
The Christie NHS Foundation Trust
Manchester, United Kingdom, M20 4BX
Actively Recruiting
16
Northern Centre for Cancer Care
Newcastle, United Kingdom, NE7 7DN
Actively Recruiting
17
Churchill Hospital
Oxford, United Kingdom, OX3 7LE
Completed
Research Team
N
Nurix Therapeutics Patient Outreach
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
12
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here